trending Market Intelligence /marketintelligence/en/news-insights/trending/9nnxsxegrmr5rgqvmblt0w2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

MediciNova brain cancer therapy nabs orphan drug status from US FDA

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

MediciNova brain cancer therapy nabs orphan drug status from US FDA

MediciNova Inc. said the U.S. Food and Drug Administration granted orphan-drug designation to MN-166, or ibudilast, as an add-on therapy to temozolomide for treating brain cancer.

Temozolomide, marketed as Temodar by Merck & Co. Inc., is a chemotherapy drug used to treat glioblastoma, an aggressive and extremely lethal form of brain cancer.

The U.S. FDA's orphan-drug designation is designed to encourage the development of rare disease therapies through incentives including seven years of marketing exclusivity.

La Jolla, Calif.-based MediciNova is a biopharmaceutical company involved in developing therapies for serious diseases with unmet medical needs. It has been marketing ibudilast in Japan and South Korea since 1989 to treat post-stroke complications and bronchial asthma. The company is developing the drug, an anti-inflammatory and neuroprotective oral agent, for progressive multiple sclerosis and other neurological conditions such as ALS and substance abuse/addiction.